ddI EC (Videx) study confirms and clarifies dosing on an empty stomach
9 January 2002. Related: Conference reports, Antiretrovirals.
Antiretrovirals
Swatch study: should we be cycling drugs?
9 January 2002. Related: Conference reports, Antiretrovirals.
New HIV drugs, resistance, pharmacogenomics
9 January 2002. Related: Conference reports, Antiretrovirals.
Antiretroviral therapy
9 January 2002. Related: Conference reports, Antiretrovirals.
Delaying antiretroviral therapy may be considered for many patients
9 December 2001. Related: Antiretrovirals.
Correlation between reduction in plasma HIV1 RNA concentration 1 week after start of antiretroviral treatment and longerterm efficacy
9 December 2001. Related: Antiretrovirals.
One week on, one week off experimental regimen might reduce the cost and toxicities of HIV therapy
9 December 2001. Related: Antiretrovirals.
Enteric coated didanosine significantly reduces nausea, bloating, GI upset
9 December 2001. Related: Antiretrovirals, Side effects.
Secondary mutations in HIV-1 protease predict treatment failure in naive patients
9 December 2001. Related: Antiretrovirals, Drug resistance.
Antiretroviral regimen complexity, self-reported adherence, and HIV patients’ understanding of their regimens: survey of women in the HERS study
9 December 2001. Related: Antiretrovirals.
Study indicates NNRTI mutations have little effect upon HIV-1 replicative capacity
9 December 2001. Related: Antiretrovirals.
Tenofovir DF 907 study
2 November 2001. Related: Conference reports, Antiretrovirals.
The Max Cmin 1 trial: indinavir/ritonavir vs. saquinavir/ritonavir
2 November 2001. Related: Conference reports, Antiretrovirals.
Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV cohort study
2 November 2001. Related: Antiretrovirals, Side effects.
European CPMP gives positive opinion for European licensing of tenofovir DF
2 November 2001. Related: Antiretrovirals.
EC approves abacavir for use by HIV-infected children
2 November 2001. Related: Antiretrovirals, Paediatric care.
Report on salvage therapy from the 39th annual meeting of the IDSA
2 November 2001. Related: Antiretrovirals, Drug resistance.
Tenofovir DF: results from phase III study released
1 October 2001. Related: Antiretrovirals.
US FDA committee recommends approval for tenofovir
1 October 2001. Related: Antiretrovirals.
HIV suppression in lymphoid tissue varies with antiretroviral regimen
1 October 2001. Related: Antiretrovirals.
Adherence rates lower than 95% are associated with virologic failure
1 October 2001. Related: Antiretrovirals.
Discontinuation rates similar between HAART regimens
1 October 2001. Related: Antiretrovirals.
African patients with non-B subtypes respond to HAART
1 October 2001. Related: Antiretrovirals.
Entry inhibitor updates from the 1st IAS
1 September 2001. Related: Conference reports, Antiretrovirals.
Durable HIV treatment benefit despite low-level viraemia: reassessing definitions of success or failure
1 September 2001. Related: Antiretrovirals.
Anticancer drug 9-nitrocamptothecin (9NC) inhibits HIV-1 replication
1 September 2001. Related: Antiretrovirals.
T-20: will long-term use weaken the immune system’s ability to fight HIV?
30 July 2001. Related: Antiretrovirals.
The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons
30 July 2001. Related: Antiretrovirals.
Ritonavir approved in Europe as pharmacokinetic enhancer for use with other antiretrovirals
30 July 2001. Related: Antiretrovirals.
Tenofovir: Gilead applies for approval, expanded access relaxed
30 June 2001. Related: Antiretrovirals.
Outcome of patients with discordant responses to HAART
17 May 2001. Related: Antiretrovirals, Treatment strategies.
Self-reported symptoms after starting HAART help predict adherence
17 May 2001. Related: Antiretrovirals, Side effects.
DuPont applies to FDA for approval of one-tablet, once daily formulation of efavirenz
17 May 2001. Related: Antiretrovirals.
Patient age influences CD4+ cell recovery with HAART
17 May 2001. Related: Antiretrovirals.
First randomised trial shows clinical benefit of TDM for people using nelfinavir or indinavir containing combinations
17 May 2001. Related: Conference reports, Antiretrovirals.
Preliminary data from four studies of double PI regimen using once daily Fortovase plus “mini dose” ritonavir
17 May 2001. Related: Antiretrovirals, Treatment strategies.
Roche and Trimeris announce US sites and investigators for T-20 phase III study; activists want wider access to drug for sickest AIDS patients
17 April 2001. Related: Antiretrovirals, Treatment access.
European marketing approval granted for lopinavir/r (Kaletra)
17 April 2001. Related: Antiretrovirals.
HIV-1 strains using the CXCR4 co-receptor are suppressed with potent therapy
17 April 2001. Related: Antiretrovirals.
Efavirenz use in HIV-positive children
17 April 2001. Related: Antiretrovirals, Paediatric care.
Drugs need not be stopped because of neutropenia in HIV-positive patients
17 March 2001. Related: Antiretrovirals, Side effects.
Capravirine clinical trials restricted: additional safety evaluation required
17 March 2001. Related: Antiretrovirals.
Gilead announces start of early access program for investigational anti-HIV agent tenofovir DF in United States and France
17 March 2001. Related: Antiretrovirals.
Differentiating within and between drug classes: sometimes it’s toxicity, sometimes its efficacy
17 March 2001. Related: Conference reports, Antiretrovirals.
HAART initiated during primary HIV infection leads to faster and more complete immune reconstitution
17 January 2001. Related: Antiretrovirals.
Viral response to antiretroviral therapy slower during acute HIV-1 infection
17 January 2001. Related: Antiretrovirals.
European Commission approves GlaxoSmithKline’s HIV triple therapy Trizivir
17 January 2001. Related: Antiretrovirals.
Lamivudine withdrawal may reactivate HBV in HIV-positive patients
17 January 2001. Related: Antiretrovirals, Hepatitis coinfection.
CPMP delivers positive opinion on Kaletra
17 January 2001. Related: Antiretrovirals.
Clinical issues arising from a single treatment interruption
17 December 2000. Related: Conference reports, Antiretrovirals.
A review of new anti-HIV drugs in development
17 December 2000. Related: Conference reports, Antiretrovirals.
Adherence and HAART: unique approaches to evaluating and improving adherence discussed
17 December 2000. Related: Conference reports, Antiretrovirals.
Importance of intensive adherence support for people with HIV-related neurological symptoms
17 December 2000. Related: Antiretrovirals.
Efavirenz side effects become long-term for over one in three
17 December 2000. Related: Antiretrovirals, Side effects.
ABT-378/r oral formulation available in UK
17 December 2000. Related: Antiretrovirals.
Trimeris, Roche to begin phase III pivotal trials of T-20 HIV fusion inhibitor
17 December 2000. Related: Antiretrovirals.
United States FDA approves Kaletra for HIV infection
17 October 2000. Related: Antiretrovirals.
Videx EC (ddI, didanosine) – food restrictions
16 September 2000. Related: Antiretrovirals.
Importance of protease inhibitor plasma levels in patients treated with genotypic-guided therapy
16 September 2000. Related: Antiretrovirals.
Flavopiridol inhibits cellular processes essential to replication of HIV
16 September 2000. Related: Antiretrovirals.
Abbott expands early-access program for ABT-378/r (Kaletra)
16 September 2000. Related: Antiretrovirals.
Roche and Trimeris announce intention to manufacture commercial supplies of anti-HIV fusion inhibitor T-20
16 September 2000. Related: Antiretrovirals.
PRO-542 shows efficacy in trial
16 September 2000. Related: Antiretrovirals.
New potential dual NNRTI-based combinations
16 August 2000. Related: Conference reports, Antiretrovirals.
Once-daily protease-based regimens
16 August 2000. Related: Conference reports, Antiretrovirals, Treatment strategies.